A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.
The top story in managed care this week was the news that Marilyn Tavenner would be resigning from her post as chief of CMS at the end of February. Andy Slavitt is slated to take over temporarily until Senate approves his appointment or another candidate is confirmed.
Although clinical trial results for Kite Pharma’s cancer immuno-therapy aren’t due until 2016, the company learned its lesson from last year’s price wars over Gilead’s hepatitis C treatment.
Lastly, we invite you to take a look at this month’s The American Journal of Managed Care as we kick off our 20th year of publication with a special commentary by co-editors-in-chief, A. Mark Fendrick, MD, and Michael E. Chernew, PhD.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen